Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Med-Tech Innovation Expo rescheduled for June 2021

Med-Tech Innovation Expo rescheduled for June 2021

Originally re-scheduled for 29 – 30 September 2020, the event will now take place from 29 – 30 June 2021. The venue for the event, the NEC, Birmingham, UK is unchanged.

The decision to postpone the event comes as a result of the unprecedented times the event industry finds itself in as a result of the global Coronavirus pandemic.

The rescheduling of the show reflects the highest regard Rapid News Group places on the health, safety, and wellbeing of its exhibitors and visitors. It also provides an appropriate solution to the uncertainties surrounding large events in the coming months.

Duncan Wood, CEO of Rapid News Group, said: “Clearly uncertainties around large gatherings and public events are still very much at the forefront of everyone’s minds. By rescheduling Med-Tech Innovation Expo to 2021 we are first and foremost ensuring the safety of our exhibitors and attendees whilst also striving to preserve the success of the event and the return on investment that our exhibitors deserve.

“We are grateful to the NEC for working alongside us to identify a dateline which we believe will work for the great majority of our exhibitors and I must also recognise the support of our key associations who have been steadfast in their support.

“We will continue in earnest with our preparations for the show to ensure it returns in 2021 bigger and better and with renewed vigour as the market recovers from the challenges and difficulties presented by the current climate.”

Visitors to the show in 2021 can look forward to a comprehensive conference programme delivered across three stages, each dedicated to enhancing a visit through the imparting of knowledge, insight and learning.

There will also be a host of interactive features, pavilions and networking events including a meetings programme and learning seminars.

Med-Tech Innovation Expo will be co-located alongside Rapid News Group’s other successful industrial events: Interplas, The UK’s No.1 Plastics show; and TCT 3Sixty, the UK’s event for 3D Printing & Additive Intelligence.

Med-Tech Innovation Expo 2021 will take place from 29 – 30 June 2021 in Hall 2 of the National Exhibition Centre (NEC), Birmingham, UK. Originally re-scheduled for 29 – 30 September 2020, the event will now take place from 29 – 30 June 2021. The venue for the event, the NEC, Birmingham, UK is unchanged.

The decision to postpone the event comes as a result of the unprecedented times the event industry finds itself in as a result of the global Coronavirus pandemic.

The rescheduling of the show reflects the highest regard Rapid News Group places on the health, safety, and wellbeing of its exhibitors and visitors. It also provides an appropriate solution to the uncertainties surrounding large events in the coming months.

Duncan Wood, CEO of Rapid News Group, said: “Clearly uncertainties around large gatherings and public events are still very much at the forefront of everyone’s minds. By rescheduling Med-Tech Innovation Expo to 2021 we are first and foremost ensuring the safety of our exhibitors and attendees whilst also striving to preserve the success of the event and the return on investment that our exhibitors deserve.

“We are grateful to the NEC for working alongside us to identify a dateline which we believe will work for the great majority of our exhibitors and I must also recognise the support of our key associations who have been steadfast in their support.

“We will continue in earnest with our preparations for the show to ensure it returns in 2021 bigger and better and with renewed vigour as the market recovers from the challenges and difficulties presented by the current climate.”

Visitors to the show in 2021 can look forward to a comprehensive conference programme delivered across three stages, each dedicated to enhancing a visit through the imparting of knowledge, insight and learning.

There will also be a host of interactive features, pavilions and networking events including a meetings programme and learning seminars.

Med-Tech Innovation Expo will be co-located alongside Rapid News Group’s other successful industrial events: Interplas, The UK’s No.1 Plastics show; and TCT 3Sixty, the UK’s event for 3D Printing & Additive Intelligence.

Med-Tech Innovation Expo 2021 will take place from 29 – 30 June 2021 in Hall 2 of the National Exhibition Centre (NEC), Birmingham, UK.

Real Time Medical Launches AI-Enabled App to Deliver Peer-Reviewed Data and Advice to Manage the COVID-19 Pandemic

Real Time Medical Launches AI-Enabled App to Deliver Peer-Reviewed Data and Advice to Manage the COVID-19 Pandemic

Real Time Medical, a leader in developing software platforms that improve the efficiency, quality and speed of medical information sharing between professionals, announced the launch of an app to help healthcare professionals and the public make better-informed decisions about COVID-19 for their patients, their families and themselves in real time, in one integrated platform.

With the support of the National Research Council of Canada Industrial Research Assistance Program, RTM’s COVID AIKnowledgeEnableTM (COVID KE) combines Artificial Intelligence-enabled search of multiple trusted, peer-reviewed medical data sources with the collective intelligence of direct physician input to deliver the most relevant and current findings and actionable advice.

Drawing exclusively on trusted sources such as the Centers for Disease Control and Prevention, the New England Journal of Medicine, the Lancet, and others, COVID KE serves as an effective information location tool that allows users to conduct their own research and educate themselves to make better decisions. Overlaid with the latest federal health guidelines for Canada and the US, the app is an effective weapon in the global fight against COVID-19.

“With a resurgence of COVID-19 infections in multiple jurisdictions in North America and around the world, and the start of a new school year, people need a way to zero-in on the valid scientific data and advice required to keep their families and patients safe – and to cut confidently through the clutter of misinformation,” said Ian Maynard, RTM’s CEO and Co-Founder.

In a July 15 presentation by the European Congress of Radiology, Dr. Marie-Pierre Revel noted that of the over 25,000 articles that have emerged about COVID-19 from multiple data sources, filtering revealed that 48 were meta-analyses and only 25 were clinical trials, underscoring the challenge in finding credible information in a tsunami of data.

“During this global pandemic, the need for credible, verifiable scientific information and advice is shared by medical professionals, policy-makers and the public, but it’s the public that is facing the biggest threat from misinformation, bad science and unsound advice,” said Dr. David Koff, RTM’s Chairman and Co-Founder. “Using the COVID KE app, you’re able to simultaneously scan multiple health data sources from around the world in seconds, which then also combines those findings with the latest recommendations from healthcare professionals around the world to make the best decisions for your family – on the go.”

Importantly, healthcare professionals and the public will also be able to use subsequent releases of RTM’s AIKnowledgeEnableTM to research the latest data on any medical symptom or ailment they choose – not just COVID-19. This quick and easy tool doesn’t store any search information, protecting the privacy of the user at all times.

The app is available for use on iPhone, Android and desktop. COVID KE will be available for download worldwide on September 4th.

To register for your download of COVID KE and for more information, please visit us at https://www.realtimemedical.com/covid-ke.

About Real Time Medical

Real Time Medical Inc. (RTM) has operated as a tele-medicine and healthcare innovation company for over 13 years, developing software platforms to improve the quality and accuracy of service delivery to medical professionals and their patients in Canada, the United States, and Europe.

Patientco’s IVR Integration Joins Epic App Orchard, Selected by Baptist Memorial Health Care

Patientco's IVR Integration Joins Epic App Orchard, Selected by Baptist Memorial Health Care

Patientco, a next-generation patient payment technology company, announced that its Interactive Voice Response (IVR) integration is now available in the Epic App Orchard marketplace and has been selected by Memphis, Tenn.-based Baptist Memorial Health Care.

As providers have cited a surge in patient calls resulting from COVID-19 and billing concerns, Baptist Memorial wanted to lift the burden from its revenue cycle management (RCM) team while also improving patient service and the overall experience.

“We wanted to give our patients the flexibility of payment by telephone in addition to our existing web and mobile options. All of these options are available 24 hours a day, seven days a week,” said Ron Wachsman, Vice President and Chief Revenue Cycle Officer at Baptist Memorial Health Care. “In addition to improving service to our patients, the IVR solution will also alleviate some of the burden on the RCM team when posting and reconciling payments.”

Epic App Orchard Integration Benefits

With Patientco’s IVR integration, patients can easily complete a payment via phone at any time, regardless of their healthcare provider’s business hours. Patients can pay using all major credit, debit and HSA or FSA cards. The integration also supports multiple languages, multiple bill payments, as well as full and partial payment workflows, ensuring a convenient, flexible experience for all patients.

For health systems, Patientco’s IVR integration automates complex patient interactions and increases self-service patient payments with a payment conversion rate of 78%. Health systems benefit from automated real-time payment posting into Epic and a single deposit that reconciles daily with their system. Since payments are automatically tokenized and processed through Patientco’s certified PCI Level 1 payments infrastructure and directly posted into Epic, health systems reduce their PCI scope.

“Since 2014, Patientco has focused on delivering proven payment integrations that ensure health systems utilize their existing technology to its full potential,” said Sean Joyce, Chief Technology Officer at Patientco. “Our solutions in App Orchard make it easy for clients to offer their patients convenient, self-service payment options and empower RCM teams to focus on the most complex patient support calls while automating the rest.”

Google Cloud Awarded Defense Contract to Prototype AI-Enabled Digital Pathology Solution

Google Cloud Awarded Defense Contract to Prototype AI-Enabled Digital Pathology Solution

The Defense Innovation Unit (DIU) has awarded a contract with Google Cloud to prototype an AI-enabled digital pathology solution at select DoD facilities. The project includes the delivery of augmented reality microscopes to DoD’s medical facilities and access to artificial intelligence (AI) models that can help military doctors with cancer detection tasks on multiple disease areas. The early access to the digital pathology platform is for research use only. DIU is the organization exclusively focused within the Department of Defense (DoD) on scaling commercial technology across the DoD.

DIU-Google Cloud Project

The goal of the DIU-Google Cloud project is to help improve the accuracy of diagnoses, assisting physicians who face an overwhelming volume of data when making diagnostic and treatment decisions–and helping lower overall healthcare costs. Working with DIU, Google Cloud will prototype the delivery of an augmented reality microscope that overlays AI-based information for doctors, providing pathology-based cancer detection tools at the point-of-care. Google’s approach will leverage TensorFlow, an open-source framework to help deliver machine-learning models as well as the Google Cloud Healthcare API for data ingestion and de-identification to maximize patient privacy.

Rollout Schedule

The initial rollout will take place at select Defense Health Agency treatment facilities and Veteran’s Affairs hospitals in the United States, with future plans to expand across the broader U.S. Military Health System. The AI-based models used to assist doctors as part of the prototype were developed from public and private datasets that were de-identified to remove personal health information and any personally identifiable information. All patient diagnostic data will solely be managed by the individual hospital or provider. Carahsoft Technology, as Google Cloud’s government distributor, played a key role in facilitating this work.

“To effectively treat cancer, speed and accuracy are critical,” said Mike Daniels, vice president, Global Public Sector, Google Cloud. “We are partnering with DIU to provide our machine learning and artificial intelligence technology to help frontline healthcare practitioners learn about capabilities that can improve the lives of our military men and women and their families.”

Carahsoft Technology, as Google Cloud’s government distributor, played a key role in facilitating this work.

The DoD’s Joint AI Center (JAIC) is providing funding for the project and technical expertise. The capabilities will also help support the JAIC’s warfighter health AI product line that aims to improve the diagnostic capability of military medicine.

Why It Matters

The Veterans Affairs Center for Innovations in Quality, Effectiveness, and Safety recently reported that within the United States, an estimated 5% of outpatient diagnoses are conducted in error. This translates to the misdiagnosis of 12 million patients each year. At the same time, the Defense Health Agency spends approximately $1.7 billion of its annual budget on cancer research, and that figure continues to grow.

This is the second contract that Google has been awarded by DIU in the past three months. In May, the two organizations announced an effort to detect, protect against, and respond to cyber threats globally.

OSU researchers use digital health data to build models predicting coronavirus death risk

India takes first step towards universal health coverage with Digital Health Mission launch

Analyzing digital health records of thousands of patients that have been admitted to hospitals around the country with coronavirus has led to the development of technology to predict the risk of death for patients with the virus.

Researchers at Oklahoma State University for Health Systems Innovation (CHSI) in both Stillwater and Tulsa are using the digital health data to build predictive models of disease risk that could improve treatment and outcomes for the patients.

“There is an urgent need to determine which COVID patients are at highest risk for bad clinical outcomes as early as possible so that plans and actions can be made to save more lives,” said Dr. Zhuqi Miao, the health data science program manager with CHSI. “With the rise in reported COVID cases in the U.S., there is no time better than right now to have a tool to predict which patients are most at risk as soon as possible.”

Meghan Sealey, an OSU statistics doctoral student, along with Miao, has analyzed data of 18,742 patients that were hospitalized by the virus from the Cerner Covid-19 data cohort, a collection of de-identified, HIPPA-compliant hospital and clinic records donated to CHSI.

Researchers at CHSI have created two models of potential mortality risk, one is based on patient data at the time of admission using demographic and historical medical conditions, and the second at the end of the first day of hospitalization using demographics, procedures, medications and known conditions.

“The models identified a similar set of medical conditions suggested by the Centers for Disease Control and Prevention as the essential risk factors for death, such as history of diabetes, respiratory disorders and hypertension, and onset of respiratory or kidney failures, but we also found some unique ones,” Miao said.

The first CHSI model can predict mortality for nearly 70 percent of patients, while the second is accurate for nearly 75 percent of patients, Miao said.

SeamlessMD raises $4M to expand connected health services

Why Telemedicine is Needed Now, More Than Ever

Toronto-based SeamlessMD announced today the closing of its $4 million Series A financing round, led by MEDTEQ+ with participation from Hikma Ventures, Anges Québec, AIoT Health and health IT entrepreneur Sanjay Malaviya.

With this funding, SeamlessMD has reached $7.4 million in total capital raised.

The company also announced that Robert Ritlop, the director of investments at MEDTEQ+, and Malaviya will be joining SeamlessMD’s board of directors.

WHAT IT DOES

The SeamlessMD platform is used by health systems to monitor and stay connected with patients throughout a variety of different healthcare journeys, including surgery, oncology and chronic condition care.

Providers can engage with patients before, during or after hospitalization through the digital platform to share care plans, educational information, health metrics and recovery progress.

It can be used as a stand-alone product or as an electronic health record integrated system. SeamlessMD is already being deployed at Stanford Medicine, Atrium Health, the Montreal Heart Institute and other locations.

WHAT IT’S FOR

The additional funds enable the company to expand upon the services they are already providing. SeamlessMD plans to deepen its library of digital care plans and improve the machine learning algorithm it employs to predict risk.

“COVID-19 has accelerated the need for health systems to deliver digital care at scale. Since the pandemic started, we have been rapidly assisting health systems to adapt to the pandemic, including new solutions for COVID-19 digital screening, patient education, and digital pre-surgery monitoring to safely resume surgery,” said Dr. Joshua Liu, the cofounder and CEO of SeamlessMD, in a statement. “We are ecstatic to be supported by forward-thinking, strategic healthcare investors who share our belief that the future of healthcare is digital.”

MARKET SNAPSHOT

Connected health has always been an important aspect of a successful care experience, but now more than ever, connected health tools are playing an even more vital role. A recent sponsored HIMSS20 Digital session covered the growing importance that connected health has during the COVID-19 pandemic for both patients and providers.

Besides SeamlessMD, companies Lumeon and Olive have recently raised $30 million and $51 million, respectively, for their connected-care platforms.

This week, Stasis Labs released a platform of its own where care teams can monitor their patients’ conditions, review trends and receive notifications when the system detects an issue.

Masimo scores extended FDA clearance for cerebral hemoglobin monitoring

Masimo scores extended FDA clearance for cerebral hemoglobin monitoring

Connected care company Masimo has landed and expanded FDA clearance for its O3 Regional Oximeter, for both somatic applications and monitoring changes in the cerebral hemoglobin.

It specifically monitors somatic tissue oxygenation saturation, and can detect changes in a patient’s hemoglobin, oxyhemoglobin and deoxyhemoglobin.

According to the company, its tool differs from peripheral pulse oximetry, because it can capture information about a “local issue’s hemoglobin oxygen saturation, both in cerebral and somatic applications.”

The new tool can be integrated with Masimo’s SedLine brain function monitor or its Root patient monitoring and connectivity platform.

WHY IT MATTERS

The company is pitching this tool as a way for medical professional to monitor cerebral or somatic tissue levels. This tool could be used is the detection of early signs of renal dysfunction, as one example, according to the company.

“O3’s expanded indication as a monitor of the oxygenation and deoxygenation components of cerebral tissue, along with the oxygen saturation of somatic tissue, represents an important milestone in helping clinicians and researchers shed additional light on how the body utilizes oxygen and in uncovering organ hypoxemia,” Joe Kiani, founder and CEO of Masimo, said in a statement.

THE LARGER TREND

Masimo has a long history in the connected health space. In recent news the company inked a deal with the NBA in July which will require all league members to measure their oxygen saturation, pulse and respiration rate on a daily basis using the company’s MightySat finger pulse oximeter.

That wasn’t the company’s only news this summer. In June it announced a new device aimed at reducing the symptoms associated with opioid withdrawal, called Bridge.

Tenacore LLC and OB Healthcare Announce Strategic Partnership

Tenacore LLC and OB Healthcare Announce Strategic Partnership

Tenacore LLC and OB Healthcare are pleased to announce they have entered into a strategic partnership, combining Tenacore’s depot-based, comprehensive healthcare technology solutions with OB Healthcare’s field-based preventative maintenance and project management solutions.

Health systems, independent service organizations (ISOs) and original equipment manufacturers (OEMs) alike face occasional variability in biomedical engineering resource availability, especially in the event of large-scale medical equipment preventative maintenance (PM) projects. As a result, there is frequent demand for additional resources to manage these types of projects, which is where OB Healthcare excels. During project assessment, units that do not pass quality control and require further evaluation and/or repair will be sent directly to a Tenacore service depot, instead of working with a separate vendor or dispositioning these units. Our partnership allows clients to work under one agreement.

“This seamless solution allows for our customers to focus on managing their many other priorities and to be assured that their equipment will be quickly returned to patient use in full working order,” said Jim Willett, CEO, Tenacore LLC.

Through the Tenacore-OB Healthcare partnership, the organizations can deliver their On-Site Project Support, Service and Repair solution. This truly differentiated solution is a hybrid medical equipment service offering, allowing both companies to deliver a combination of on-site project management and depot-based service and repair.

Leveraging proprietary software technology developed by OB Healthcare, the organizations are able to execute against large scale projects with unparalleled speed and accuracy. “This software is exclusively tailored for the technicians performing preventative maintenance,” said Austin Otto, President, OB Healthcare. “It was designed with accurate and live reporting, enabling real-time status updates and the electronic delivery of service reports and documentation to a customer’s existing computerized maintenance management system (CMMS).”

The healthcare industry is continuing to evolve, and more demands are being placed on the healthcare technology management (HTM) community than ever before. The combined capabilities and market leading expertise of Tenacore and OB Healthcare represents a partnership designed to further support the HTM community by addressing these additional demands in a new and differentiated way.

About OB Healthcare

Founded in 2007, OB Healthcare is a national clinical engineering company and a leading provider of specialized biomedical services. Using advanced processes, nationwide resources, and innovative proprietary software, OB Healthcare provides a powerful competitive advantage that can help save time and money.

About Tenacore

Tenacore LLC is a healthcare technology management company providing clinical equipment lifecycle solutions to the global healthcare technology community through quality service delivery and dedication to continuous improvement. Specializing in the depot-based service and repair of a broad range of medical equipment, Tenacore’s expansion across the United States paired with its multi-vendor service expertise and scalability uniquely positions the company to offer a cost effective and quality alternative to site-based service. In February of 2020, The Courtney Group based in Newport, CA, collaborated with Indianapolis based Centerfield Capital Partners to invest in the acquisition of Tenacore LLC.

How much water should you drink per day?

How much water should you drink per day?

Water is something that cannot be left behind when discussing of a healthy lifestyle. We all know very well that water is a vital element not only for flora and fauna but also for humans. Meanwhile, when the body lacks water, side effects such as poorer muscle tone, indigestion, a weakened nervous system and an increased risk of vascular and cardiovascular disease can begin to occur. Since such a perspective doesn’t really sound charming, the question arises – how much water should you drink a day to be healthy?

Doctors’ recommendations

When it comes to the amount of water you need to drink every day, doctors’ recommendations vary. It is generally stated that eight glasses of water a day are necessary to maintain one’s vital functions. Other experts state that the amount of water you need to drink per day can be calculated based on your height. According to them, 1 cm tall requires 10 ml of water. This means that if your height is 170 cm, you should drink 1.7 liters of water a day.

You can also find a variety of detailed calculations that can provide you with the information of water amount you need to drink per day, depending on your body mass index, physical activity and its‘ intensity, stress level at work and so on.

Water uptake with food

Some people say they get enough water with food. This is only partly true. In fact, vegetables and fruits make up about 90% of water, meat and bread about 50%. However, even having proper breakfast, lunch and dinner, as well as snacking on fruits or vegetables between meals, the body will not get enough water to meet the basic needs. Food in the diet of a healthy person usually provides about 20 percent of the water he or she has to drink per day in order to maintain good health. However, according to WaterOnTop.com research, there are some foods whose water content percentage is above 90% or even 95%. A few examples: cucumber – 96% of water content, iceberg lettuce – 96%, radishes – 95%, watermelon – 92%. These and other similar foods will help you stay hydrated all day long if you will integrate them into your nutrition.

Do not worry to consume too much water

Usually people drinks water only when they feel thirsty. However, this is not an example to follow. When a person feels thirsty, his body is already short of about one liter of water. It’s like a red light in the car dashboard that indicates you should go to a service center as soon as possible. Therefore, it is best to drink water constantly without waiting to feel thirsty.

In principle, it is not very important to adhere strictly to a norm that is calculated to be sufficient for your body. For example, you need to use more water on a hot summer day or during sports. In other words, the amount of water needs to be adjusted according to the situation in certain cases.

Also, don’t be afraid to consume too much water. Excess water is successfully eliminated by the body and it has no side effects on the body.

Not just quantity but also quality.

It should be mentioned that it is incredibly significant not only to drink the body’s daily required amount of water but also to ensure that the water is of high quality. After all, if you drink contaminated water that contains too many nitrites, nitrates, other toxic compounds, bacteria or chemicals, you will definitely have health problems soon. In other words, drinking hazardous water you will not strengthen your body but on the contrary, it will make you sick.

It is important to note that harmful substances in water may not change the taste, smell or color of the water. Therefore, it is possible that you are drinking harmful water without knowing it. Therefore, it is especially important to make sure that the water you use every day is of high quality and absolutely clean.

Choosing high quality water

To ensure that you and your family drink quality water, you can choose between the two the most reliable methods. You can drink either distilled water or use water filtered with Reverse Osmosis systems. These are the most popular choices among people who care about the quality of their drinking water for daily use. However, the question “Which one of these two options would be better?” is difficult to answer as everyone chooses according to their own and family’s needs.

There are two types Reverse Osmosis water systems: under sink and countertop. The first one has superiority because of its speed and large amount of water treated, the second one because of its convenience, compactness and easy transporting. It can be mentioned that the Reverse Osmosis filter is often chosen by those for whom distilled water looks a bit flat and tasteless. While the water filtered by this system retains its flavor. However, this water is not as pure as that distilled.

Whichever of these options you choose, you can be sure that you are drinking water that allows you and your beloved ones to maintain excellent physical and emotional health.

Medtronic Cryoablation Superior to Drug Therapy for Symptomatic Paroxysmal Atrial Fibrillation

Medtronic plc, the global leader in medical technology, announced clinical trial results demonstrating superiority of the Arctic Front™ Advance Cardiac Cryoballoon and Freezor® MAX Cardiac CryoAblation Catheter for the first-line treatment (prior to drug therapy) of recurrent symptomatic paroxysmal atrial fibrillation (PAF) compared to antiarrhythmic drug (AAD) treatment. Primary results of the randomized STOP AF First trial were presented as a late breaking clinical trial at the European Society of Cardiology (ESC) Congress 2020 Digital Experience. Additionally, 12-month outcomes from the Cryo-FIRST trial showed a significant improvement in atrial fibrillation-related quality of life with the use of the Medtronic cryoablation system compared to anti-arrhythmic drug therapy in patients who had not previously received antiarrhythmic drugs to treat their symptomatic PAF.

Atrial fibrillation (AF) is a progressive condition that impacts more than 33 million people worldwide. Without early intervention, progression of the condition is associated with a higher rate of cardiovascular admissions, heart failure hospitalization, and mortality, along with a reduced quality of life. Antiarrhythmic drug therapy is currently the standard first-line treatment for patients with AF; however, AF recurs in approximately 50% of patients treated with AADs within a year of therapy onset. In addition, AAD therapy frequently causes side effects that can lead many patients to discontinue treatment. Cryoablation uses cold energy (freezing) delivered through an inflatable balloon to create scar tissue to interrupt unwanted electrical pathways in the heart.

STOP-AF First Primary Results

The STOP-AF First trial enrolled 225 patients at 24 sites in the United States and was designed to evaluate the safety and effectiveness of the Medtronic cryoablation system to treat recurrent symptomatic PAF in patients who had not previously received antiarrhythmic drugs for their AF. A total of 203 patients randomized to cryoablation (104 in treatment arm) or AAD therapy (99 in control arm) received treatment and were followed for 12 months.

Results showed superiority of cryoablation for maintaining freedom from AF, atrial tachycardia and atrial flutter, with treatment success achieved in 75% of patients in the catheter ablation group versus 45% in the AAD group (P<0.0001). Furthermore, the trial revealed a low rate of safety events with catheter ablation as a first-line therapy (1.9%). Previous studies have consistently demonstrated a low rate of serious complications with cryoablation in drug refractory patients; the STOP AF First study furthers these observations specifically to patients who had not previously received antiarrhythmic drugs to treat their symptomatic PAF. 

Cryo-FIRST Quality of Life Results

Cryo-FIRST was a randomized, multicenter trial that enrolled 220 patients at 18 sites in nine countries across Europe, Australia and Latin America. Similar to STOP AF First, this trial found that the Medtronic cryoablation system is superior to AAD therapy for the prevention of atrial arrhythmia recurrence in PAF patients who have not previously been treated with drug therapy.

New quality of life findings from the trial, also presented at ESC 2020, showed the Medtronic cryoablation solution resulted in a significant improvement in AF-specific, health-related quality of life at 12 months compared to AAD therapy.

“More than half of patients with symptomatic AF do not experience a reduction in AF with antiarrhythmic drugs, effectively delaying their therapy and leaving a critical need for an alternative first-line treatment,” said Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm and Heart Failure and the Cardiac Ablation Solutions divisions, which are part of the Cardiac and Vascular Group at Medtronic. “Not only do the STOP AF First findings show cryoablation is a potential first-line treatment for these patients, the Cryo-FIRST results show encouraging benefits of this treatment approach on these patients’ quality of life.”

The Arctic Front Advance Cryoablation System is approved in Europe for the treatment of AF. The United States Food and Drug Administration (FDA) recently expanded the indication for Medtronic cryoablation therapy to include treating patients with symptomatic, recurrent persistent AF, in addition to patients with drug refractory, recurrent, symptomatic paroxysmal AF. Results of the STOP-AF First trial have not been reviewed by the FDA.

“The strong evidence from these trials will help bring cryoablation treatment to more patients suffering from AF earlier in the course of their disease,” said Rebecca Seidel, vice president and general manager of Cardiac Ablation Solutions. “Medtronic has very robust clinical evidence supporting the Arctic Front Family of Cardiac Catheters as a first line therapy for paroxysmal AF, and for paroxysmal and persistent AF patients whose condition is unresponsive to drug therapy.”

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic

Medtronic plc, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Translate »